Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension

• Published in: Genes Vol. 11; no. 10; p. 1158
• Main Authors: Castaño, Jair Antonio Tenorio, Hernández-Gonzalez, Ignacio, Gallego, Natalia, Pérez-Olivares, Carmen, Ochoa Parra, Nuria, Arias, Pedro, Granda, Elena, Acebo, Gonzalo Gómez, Lago-Docampo, Mauro, Palomino-Doza, Julian, López Meseguer, Manuel, del Cerro, María Jesús, PAH Consortium, Spanish, Valverde, Diana, Lapunzina, Pablo, Escribano-Subías, Pilar
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2020; MDPI
• Subjects: and genetics; Cardiac catheterization; Classification; Connective tissue diseases; Coronary artery disease; Diagnosis; digenic inheritance; Disease; DNA sequencing; Ethics; Etiology; Genes; Genetic aspects; Genetic counseling; Genetic screening; Heart diseases; Heredity; Hypertension; Intubation; massive parallel sequencing; Methods; Mortality; Mutation; NGS; Nucleotide sequencing; pulmonary arterial hypertension; Pulmonary arteries; Pulmonary hypertension; Quality control; Survival analysis; Spain; United States > US; Indianapolis Indiana
• ISSN: 2073-4425; 2073-4425
• DOI: 10.3390/genes11101158

Pulmonary arterial hypertension is a very infrequent disease, with a variable etiology and clinical expressivity, making sometimes the clinical diagnosis a challenge. Current classification based on clinical features does not reflect the underlying molecular profiling of these groups. The advance in massive parallel sequencing in PAH has allowed for the describing of several new causative and susceptibility genes related to PAH, improving overall patient diagnosis. In order to address the molecular diagnosis of patients with PAH we designed, validated, and routinely applied a custom panel including 21 genes. Three hundred patients from the National Spanish PAH Registry (REHAP) were included in the analysis. A custom script was developed to annotate and filter the variants. Variant classification was performed according to the ACMG guidelines. Pathogenic and likely pathogenic variants have been found in 15% of the patients with 12% of variants of unknown significance (VUS). We have found variants in patients with connective tissue disease (CTD) and congenital heart disease (CHD). In addition, in a small proportion of patients (1.75%), we observed a possible digenic mode of inheritance. These results stand out the importance of the genetic testing of patients with associated forms of PAH (i.e., CHD and CTD) additionally to the classical IPAH and HPAH forms. Molecular confirmation of the clinical presumptive diagnosis is required in cases with a high clinical overlapping to carry out proper management and follow up of the individuals with the disease.